Despite recent headlines declaring the success of an experimental Ebola vaccine, the world is not fully prepared for future epidemics — and not in position to use vaccines to prevent another deadly outbreak, a report published Tuesday warned.

The report raised serious concerns about the work that remains to be done on Ebola vaccines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I hope you received my request for a subscription to stat news free I hope. Terrific.I know a reporter who would like a job. Me

  • Good article.
    Typical everything comes down to money with these drug companies. Greed is going to destroy us all, mark my words.

  • Although this fine article is devoted to vaccines

    Were we to have and employ vaccines to prevent the conditions discussed here and more, the war would not be won, just the current battle, since In all probability we can look forward to the continuing arrival of new pathogens as well as old ones sporting new genetic alterations. So, vaccines while appropriate and necessary, cannot be the end-all in our contests unless they are broad spectrum, multivalent in development and effect rather than being aimed at a single specific organism, a treacherous path at best because of the necessity of manipulating immunological characteristics at the bench. When we consider developing antitoxins, the same caution rings true. But here I suspect that the quest for a wider coverage can be more readily carried out by the pharmaceutical chemist.

    There is on hand a physical, broad-spectrum device that removes viral pathogens and their products that prevent recognition of the virus by the immune system from circulating blood. Developed by protein chemists at Aethlon Medical, Inc. in San Diego, CA, this effective unit is called the Hemopurifier®.

    It has been shown to remove numerous pathogens as HIV, HCV, Ebola, Dengue, and chikungunya and is approved for use against the latter three in the USA. Recently, in studies conducted under a DARPA contract, it has trapped and removed the toxins associated with MRSA.

    The Hemopurifier®, is not simple to engage; it uses the same system that is employed in hemodialytic therapy of patients with kidney failure (ESRD), and the patient must be prepared for blood access and return as in conventional hemodialysis. But, when treating a patient facing imminent death due to organ failure from toxemia, there should be no limit to the life-saving possibilities considered and employed.

    When the next epidemic or pandemic outbreak occurs, we must be better prepared to meet it rapidly and effectively, since mobilizing to develop vaccines, antibiotics, and antitoxins specific for hitherto unknown pathogens is time-consuming, costly, and often futile while the Hemopurifier® is at hand.

    In considering the defense of our country, we must think well beyond military hardware to possible biological terrorism and warfare. Historically, sepsis has been the primary cause of death on the battlefield.

    The details of the technology and of the patient’s post-recovery activities are presented at .

    Summarized by the author of Nash FD (2017) A Complementary Approach in the Treatment of MRSA: Capturing and Removing the Toxins. Int J Vaccines Vaccin 4(1):00071

  • Good article. Many Americans wish there was equal attention to the epidemic of Lyme and tick-borne co-infections that are impacting the health and futures of their families, friends and co-workers. In addition to prevention, much more research is needed on effective treatments when not caught early and the lifecycle becomes established in the body. Additionally, on diagnosing and treating the synergistic impacts of other stressors on the immune system, and how they might influence disease, treatment, recovery and relapse processes. These include mold toxicity and heavy metals exposure, especially to those with genetic susceptibility to those factors.

  • What is the current status on the development for a zika vaccine? Many argue how zika threatens Brazil. But in Puerto Rico it may threaten one third of the population there in the midst of a major economic crises not within the control of this US colonial territory. Shameful!!!!!

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy